Mavatar uses AI and digital twin technology to create personalized medication plans for patients. By simulating drug interactions and individual patient responses, the platform aims to prevent adverse drug reactions and optimize treatment outcomes.
Funding
$3.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for determining personalized medication plans often rely on generalized data, failing to account for individual patient variations and potentially leading to adverse drug reactions or suboptimal treatment outcomes. Traditional drug development processes also lack efficient methods for identifying drug targets and predicting drug efficacy across diverse patient populations.
Solution
Mavatar offers an AI-driven precision medicine platform that leverages digital twin technology to create personalized treatment strategies and accelerate drug discovery. The platform utilizes Deep Integrated Network Analysis (DINA), a proprietary framework that analyzes extensive biomedical datasets to model disease biology at a systems level. By creating virtual representations of both patients and diseases, Mavatar enables in-silico simulations of treatment responses, allowing clinicians to predict optimal therapies and pharmaceutical companies to identify promising drug candidates. Mavatar's approach facilitates data-driven decisions, improving treatment outcomes, optimizing clinical trials, and reducing healthcare waste through personalized, predictive, and effective care. The platform supports two primary areas: Mavatar Discovery for pharmaceutical companies and researchers to accelerate drug development, and Mavatar Precision for clinicians to make personalized treatment decisions.
Target Audience
Mavatar serves pharmaceutical companies, biotech firms, academic researchers, and clinicians seeking to accelerate drug development, uncover new therapeutic insights, and deliver personalized treatment decisions.
Features
- DINA (Deep Integrated Network Analysis) framework for decoding disease biology
- Integration of millions of transcriptomic and proteomic datasets to capture real-world biological variation
- Digital twins of patients and diseases for simulating treatment responses
- Tissue-specific gene interaction networks to reveal concealed disease mechanisms
- AI algorithms for matching patients to molecularly similar subgroups
- Therapy recommendations based on a relative scoring system
- Cross-disease learning to uncover shared biological mechanisms and repurposing opportunities
- Support for modeling any condition with sufficient molecular data